Golden
Codexis

Codexis

An enzyme engineering company supplying products to commercial customers and developing proteins for its own portfolio of clinical biologics.

Codexis was incorporated in 2002 by Maxygen to develop an enzyme engineering technology platform, completing a spin-off in 2010 as a separate publicly-listed company on the NASDAQ exchange. Today it has three major focus areas: supplying engineered enzymes to commercial customers in pharmaceutical manufacturing, food ingredient manufacturing, and other industrial areas; licensing its CodeEvolver technology package to companies interested in engineering enzymes in-house; and developing a clinical portfolio of biologics created from its technology platform. In 2018 the company expects to generate $60 million to $63 million in revenue for the full year, including $25 million to $28 million from products in commercial supply contracts.

Timeline

People

Name
Role
Related Golden topics

Adam Litle

Employee



Barry Ettenger

Employee



Brian Kirshner

Employee



Christopher McCarthy

Employee



Darla Llewelyn

Employee



David J. Galgoczy

Employee



David McCaman, CPA

Employee



Dayna H. Johnson

Employee



Diana Maichin

Employee



Gordon Sangster

Senior Vice President, CFO



Gregg Ringold

Employee



Gregory Miller

Employee



Jim Lalonde

Senior Vice President of R&D



John Nichols

President, CEO



John Vu

Employee



Joshua Geilhufe

Employee



Kamrin Mac Knight

Employee



Kiyoung Paik

Employee



Lana Spencer, PG, CHMM, QISP

Advisor



Lisa Moore

Employee



Lucia Guh-Siesel

Attorney



Melvina Ho

Employee



Michael Aldridge

Corporate and Strategic Development



Monica Bhatia

Employee



Navneet Chagger

Employee



SHOW ALL (31)

Further reading

Title
Author
Link
Type







Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services